News
Ipsen licenses Simcere ADC in $1bn-plus deal
Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.
News
AZ's ATR inhibitor ceralasertib flunks lung cancer test
AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.
News
Ambros' $125m for pain disorder drug, and other financings
Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
News
J&J's subcutaneous Rybrevant cleared by FDA
J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
News
Datroway filed for TNBC in EU after data delay
Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
